Joshua Weisbort

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

Uri Goldbourt, Solomon Behar, Henrietta Reicher-Reiss et al. · The American Journal of Cardiology · 1993 · 157 citations

Medicine, Cardiology, Internal Medicine +17

Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: Twenty-year follow-up of the donolo-Tel Aviv prospective coronary artery disease study

D. Brunner, Joshua Weisbort, Nissim Meshulam et al. · The American Journal of Cardiology · 1987 · 155 citations

Medicine, Cardiology, Clinical Cardiology +13

Multivariate analysis of the twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary artery disease study and the usefulness of high density lipoprotein cholesterol percentage

Gregory Livshits, Joshua Weisbort, Nissim Meshulam et al. · The American Journal of Cardiology · 1989 · 43 citations

Medicine, Biostatistics, Cardiology +15

Thromboxane, prostacyclin, beta-thromboglobin, and diabetes mellitus.

D. Brunner, James R. Klinger, Joshua Weisbort et al. · PubMed · 1984 · 14 citations

Medicine, Endocrinology, Internal Medicine +10

Serum cholesterol and high density lipoprotein-cholesterol in coronary patients and healthy persons

D. Brunner, Joshua Weisbort, K Loebl et al. · Atherosclerosis · 1979 · 11 citations

Medicine, Cardiology, Clinical Cardiology +16